Acquisition Pending
Eli Lilly acquisition of Curevo Vaccine
US$1.5bn consideration
Announced 26 May 2026
Advisers
Curevo Vaccine
Target
- Financial adviser
- Legal adviser
- Cooley
Team: Bill Roegge, Lindsey O'Crump Crow, Jamie Leigh, Colleen Badgley, Sonya Erickson, Jane Adams, Mike Tuscan, Sarah Buchik, Phoebe Huang, Jordan Phelan, Amarantha Zaniker-Gomez, Joe Honeycutt, Nancy Kyei, Stephanie Gentile, Michael Bergmann, Alison Freeman-Gleason, Navya Dasari, Patrick Sharma, Alexander Ellebracht, Nathan Alamillo, Yasmine Ebrat, Jennifer Fuentes
Eli Lilly
Acquirer
Not disclosed
- Target
- Curevo Vaccine
- Acquirer
- Eli Lilly
- Target based in
- United States (unverified)
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Drug Development
In the league tables
Similar deals
- Servier acquisition of Sevasemten and Edgewise muscular dystrophy business Jun 2026 · US$1.6bn · Biotech
- Lilly acquisition of Vaccine Company May 2026 · US$1.6bn · Biotech
- Gilead acquisition of Ouro Medicines Mar 2026 · US$1.7bn · Biotech
- Eli Lilly and Company acquisition of Ventyx Biosciences Jan 2026 · US$1.2bn · Biotech
- Incyte acquisition of Vega Therapeutics Jun 2026 · US$1.3bn · Biotech
Sources
- 2026 Centerview Partners: Financial advisor to Curevo on its sale to Eli Lilly centerviewpartners.com
- 26 May 2026 Curevo Vaccine to be Acquired by Eli Lilly for up to $1.5 Billion cooley.com
